Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Photo by Kirill Kukhmar/TASS via Getty Images
Emulate, a Boston-based developer of "organs-on-chips," raised $36 million in new venture capital funding led by Peter Thiel's Founders Fund.
Why it's a big deal: Because this technology could reduce the large number of animals used each year in pharmaceutical lab testing, without sacrificing efficacy.
- Emulate currently has partnerships with such drug-makers as AstraZeneca, Merck, Roche, Takeda and Johnson & Johnson.
- Other investors in the "Series C" round include ALS Investment Fund, SciFi VC and Glass Wall Syndicate.
More detail from Xconomy's Frank Vinluan:
"The translucent Emulate chips, roughly the size of a AA battery, have tiny channels lined with human cells and tissue. These chips are engineered to recreate the physiology and mechanical forces encountered by the cells of an organ, such as the flow of blood or air. Emulate has developed organ chips for the liver, intestine, lung, and the brain. Those chips are part of a broader system that includes instruments for conducting experiments and software to analyze data and model different diseases."